Physician profile
Dmitry Shuster
NPI 1053623504
$350,692.16
in general payments reported to CMS, 2019-2025
25 companies · $117K in 2025
The $117K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,541 · 2020: $19K · 2021: $30K · 2022: $67K · 2023: $53K · 2024: $57K · 2025: $117K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $191K · Travel and Lodging: $26K · Food and Beverage: $8,309 · Consulting Fee: $1,725 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $191,065.00 |
| Travel and Lodging | $25,742.91 |
| Food and Beverage | $8,308.51 |
| Consulting Fee | $1,725.00 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $297,892.98 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Madrigal Pharmaceuticals | $40,189.87 | 2025 | Rezdiffra |
| Perspectum Diagnostics LTD | $6,356.85 | 2022-2025 | Livermultiscan |
| Olympus Corporation of The Americas | $1,411.08 | 2022-2023 | Single Use Electrosurgical Hemostatic Forceps, Single Use Electrosurgical Knife Kd-655 |
| Boston Scientific Corporation | $1,362.70 | 2024-2025 | Spyglass, Overstitch Endoscopic Suturing System |
| Covidien LP | $1,014.38 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $659.95 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Endogastric Solutions, INC | $648.15 | 2019-2021 | |
| Janssen Biotech, INC. | $553.02 | 2020-2025 | Tremfya, Stelara |
| Genzyme Corporation | $201.52 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $72.07 | 2022-2024 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.14 | 2022 | |
| Janssen Pharmaceuticals, INC | $44.72 | 2019-2025 | |
| Celgene Corporation | $43.41 | 2022 | |
| Aimmune Therapeutics, INC. | $20.68 | 2025 | Zenpep |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $20.09 | 2023 | Hyrimoz |
| Gilead Sciences, INC. | $19.07 | 2025 | |
| Phathom Pharmaceuticals, INC. | $18.23 | 2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $17.74 | 2025 | |
| Ardelyx, INC. | $17.35 | 2024 | Ibsrela |
| Olympus America INC. | $17.11 | 2024 | Endoclot Phs |
| Nestle Healthcare Nutrition INC. | $16.08 | 2022 | |
| Amgen INC. | $15.23 | 2022 | |
| Ambu INC. | $11.74 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitry Shuster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.